Suppr超能文献

剂量研究性临床试验中的样本量:系统评价

Sample sizes in dosage investigational clinical trials: a systematic evaluation.

作者信息

Huang Ji-Han, Su Qian-Min, Yang Juan, Lv Ying-Hua, He Ying-Chun, Chen Jun-Chao, Xu Ling, Wang Kun, Zheng Qing-Shan

机构信息

Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.

Department of Computer, College of Electronic and Electrical Engineering, Shanghai University of Engineering Science, Shanghai, People's Republic of China.

出版信息

Drug Des Devel Ther. 2015 Jan 7;9:305-12. doi: 10.2147/DDDT.S76135. eCollection 2015.

Abstract

The main purpose of investigational phase II clinical trials is to explore indications and effective doses. However, as yet, there is no clear rule and no related published literature about the precise suitable sample sizes to be used in phase II clinical trials. To explore this, we searched for clinical trials in the ClinicalTrials.gov registry using the keywords "dose-finding" or "dose-response" and "Phase II". The time span of the search was September 20, 1999, to December 31, 2013. A total of 2103 clinical trials were finally included in our review. Regarding sample sizes, 1,156 clinical trials had <40 participants in each group, accounting for 55.0% of the studies reviewed, and only 17.2% of the studies reviewed had >100 patient cases in a single group. Sample sizes used in parallel study designs tended to be larger than those of crossover designs (median sample size 151 and 37, respectively). In conclusion, in the earlier phases of drug research and development, there are a variety of designs for dosage investigational studies. The sample size of each trial should be comprehensively considered and selected according to the study design and purpose.

摘要

研究性II期临床试验的主要目的是探索适应症和有效剂量。然而,目前尚无关于II期临床试验确切合适样本量的明确规则,也没有相关的已发表文献。为了探究这一问题,我们在ClinicalTrials.gov注册库中使用关键词“剂量探索”或“剂量反应”以及“II期”搜索临床试验。搜索的时间跨度为1999年9月20日至2013年12月31日。我们的综述最终纳入了总共2103项临床试验。关于样本量,1156项临床试验每组的参与者少于40人,占所审查研究的55.0%,而在所审查的研究中,只有17.2%的研究单组患者病例数超过100例。平行研究设计中使用的样本量往往大于交叉设计(中位数样本量分别为151和37)。总之,在药物研发的早期阶段,剂量研究性试验有多种设计。每个试验的样本量应根据研究设计和目的进行综合考虑和选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a955/4294651/b7bd049b000b/dddt-9-305Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验